In addition, the developed bioplatform made possible the direct assessment of ErbB2 status in intact breast cancer cells, thus demonstrating that the new magnetoimmunosensing bioscaffold constitutes a useful and truthful analytical tool in the diagnosis of breast cancer by either ErbB2 protein determination in serum or detection of breast cancer cell status. This evidence concerns the gene ERBB2 and breast cancer.